MEET YOUR MATCH

Participants in the BioBusiness Summer School get the opportunity to learn more about specific positions and organisations within the industry during 30 or 45-minute Meet your Match sessions. We have selected the following professionals for this years' Meet your Match:

About Wim Dokter

Wim has served as CSO of Byondis since 2019. Wim is a seasoned scientist, having operated within the pharma and biotech industries for over 20 years. He has a proven track record of leading drug development programs with large international and multidisciplinary teams to successfully reach key milestones, including delivery of several clinical drug candidates in oncology, autoimmunity and diabetes. Preceding his appointment to CSO, Wim was Executive Vice President Preclinical at Synthon Biopharmaceuticals. Prior this, he was Director of Pharmacology and Immunology Program Leader at Schering-Plough, which ultimately merged with Merck & Co. (MSD). Before this, he built his career in R&D through a progression of roles at Organon.Wim’s scientific expertise is exemplified by the 50+ peer-reviewed publications in scientific journals that he has co-authored. Wim holds an MSc in (Bio)Chemistry and a PhD in Hematology and Oncology, both from the University of Groningen, the Netherlands.

About Byondis

Driven to improve patients’ lives, Byondis is an independent, privately held, clinical stage biopharmaceutical company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. The company is developing new biological entities (NBEs) and new chemical entities (NCEs) using proprietary molecular concepts, such as ByonZine®, its duocarmazine linker-drug (LD) technology and ByonShieLD®, its site-specific conjugation technology, to generate next generation antibody-drug conjugates (ADCs). 

Byondis’ broad portfolio comprises preclinical as well as early- and late-stage clinical development programs, including the anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985, Phase III). The company has a dedicated team of around 400 staff, including highly educated scientists and skilled technicians working in state-of-the-art Research and Development laboratories and Good Manufacturing Practice manufacturing facilities at its Nijmegen campus in the Netherlands. Byondis regularly collaborates with globally renowned biotechnology and pharmaceutical companies and academic research institutions.



Gemma Moiset

Gemma Moiset obtained her PhD in Life Sciences from the University of Groningen in the lab of Prof. Dr. Bert Poolman. Immediately after, she joined the Netherlands Cancer Institute (NKI) as a postdoc with Prof. Dr. Huib Ovaa where she worked on the design and screening of inhibitors for oncotargets. Two years after, she joined the biotech AIMM Therapeutics as a Scientist for five years, where she contributed to the discovery and development of novel monoclonal antibodies from cured cancer patients. Recently, she has joined the contract research organization Charles River Laboratories as Group Leader.

About Charles River Laboratories

 Charles River is an early-stage CRO with a diverse portfolio of discovery and safety assessment services to support clients from target identification through preclinical development. We also provide products and services to support clinical laboratory testing needs and manufacturing activities. We are passionate about our role in improving the quality of people’s lives and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. Charles River is an early-stage CRO with a diverse portfolio of discovery and safety assessment services to support clients from target identification through preclinical development. We also provide products and services to support clinical laboratory testing needs and manufacturing activities. We are passionate about our role in improving the quality of people’s lives and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.



Ernst Geutjes

Ernst has over 10 years of experience in cancer research, oncology drug development and venturing. Ernst holds a PhD in molecular cancer genetics from the Netherlands Cancer Institute (NKI-AvL) after which he continued his career as business developer at the research- and technology organization TNO, where he had a role in spinning-of biotech companies. As partner at Aglaia he is responsible for analysis of investment proposals, scouting of new investment opportunities and offers strategic and operational support to Aglaia’s portfolio companies. He was managing director for Sapreme Technologies and is currently a board observer for Macrophage Pharma and Sapreme Technologies.

About Aglaia

Aglaia Oncology Funds is an investment firm which fully specializes in and focusses on investing in oncology ventures. Aglaia has been in operation since 2004. The team has decades of experience in cancer research and oncology drug development, having been involved in the development of more than 100 oncology products. Aglaia has invested in 13 early stage companies, of which 6 were founded by Aglaia. Aglaia’s vision is that when stellar science is translated into great medicines for cancer patients, financial rewards for those involved in this process will ultimately follow. The continuous strategic and operational involvement of the team with portfolio companies has contributed to a marked success rate in transitioning early-stage portfolio companies to clinical-stage companies. By doing so, Aglaia has de-risked and matured these companies up to the level at which they became attractive candidates for licensing, acquisition or IPO. Examples are Merus, which became listed on the NASDAQ and Syntarga, which was sold to Synthon. More importantly, 800 cancer patients have been treated so far with investigational drugs developed by Aglaia’s portfolio companies.


Veerle van Meervelt

Veerle van Meervelt obtained a PhD in Biochemistry in the lab of Prof. Dr. Maglia at the University of Leuven and the University of Groningen. Her broad background in biochemistry together with a strong desire to contribute to diagnostic products brought Veerle to GenDx. Early 2018, she joined the support team as technical support specialist. In this function she could fully use her talent to explain complicated subjects in a clear way. After 2.5 years she started leading the GenDx support team. As Manager Support, Veerle is dedicated to ensure customers get the best out of GenDx products.

About GenDx

GenDx supports diagnostic laboratories with the newest technologies for high resolution HLA typing by Next Generation Sequencing strategies and Chimerism monitoring, tailored to enhance the outcome of transplantation. In GenDx we believe that progress can be best achieved through partnerships but also by keeping our independent position and a strong focus on education of the end-users. The close-knit management team aims to create a working atmosphere with ample room for personal development, job satisfaction and a transparent way of communication. At the moment GenDx has about 60 employees. 


Powered by:
BCF Courses BV   

    Connect with us                  

Join BioBusiness Summer School

Privacy Policy
Terms & Conditions 

Chamber of Commerce: 75874415
         
  
  
  
                                    

        KEEP ME INFORMED
    

© Copyright 2025 by BCF Courses